You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,693,989

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,693,989

Title:	N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Abstract:	This invention provides compounds of Formula I ##STR00001## wherein B, G, A, E, R.sup.1, R.sup.2, R.sup.3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
Inventor(s):	Lyssikatos; Joseph P. (Piedmont, CA), Hicks; Julie Marie (Erie, CO), Marmsater; Fredrik P. (Boulder, CO), Zhao; Qian (Superior, CO)
Assignee:	Array Biopharma, Inc. (Boulder, CO)
Application Number:	14/034,361
Patent Claims:	1. A pharmaceutical composition comprising a compound having the Formula: ##STR00354## or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier. 2. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00355## or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00356## or a pharmaceutically acceptable salt thereof. 4. The composition of claim 1, wherein an anti-tumor agent is administered in combination. 5. The composition of claim 4, wherein the anti-tumor agent is an anti-metabolite. 6. The composition of claim 5, wherein the anti-metabolite is 5-fluorouracil. 7. The composition of claim 4, wherein the anti-tumor agent is an antimitotic agent. 8. The composition of claim 7, wherein the antimitotic agent is selected from the group consisting of taxol and taxotere. 9. The composition of claim 4, wherein the anti-tumor agent is an inhibitor of growth factor function. 10. The composition of claim 9, wherein the inhibitor of growth factor function is trastuzumab. 11. The composition of claim 4, wherein the anti-tumor agent is an antiangiogenic agent. 12. The composition of claim 11, wherein the antiangiogenic agent is bevacizumab. 13. A method of treating a cancer that over-expresses HER2 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound having the Formula: ##STR00357## or a pharmaceutically acceptable salt thereof; wherein the cancer is breast cancer. 14. The method of claim 13, wherein the compound has the Formula: ##STR00358## or a pharmaceutically acceptable salt thereof. 15. The method of claim 13, wherein the compound has the Formula: ##STR00359## or a pharmaceutically acceptable salt thereof. 16. The method of claim 13, wherein the compound has the Formula: ##STR00360## 17. The method of claim 13, wherein the compound has the Formula: ##STR00361## 18. The method of claim 13, wherein an anti-tumor agent is administered in combination. 19. The method of claim 18, wherein the anti-tumor agent is an anti-metabolite. 20. The method of claim 19, wherein the anti-metabolite is 5-fluorouracil. 21. The method of claim 18, wherein the anti-tumor agent is an antimitotic agent. 22. The method of claim 21, wherein the antimitotic agent is selected from the group consisting of taxol and taxotere. 23. The method of claim 18, wherein the anti-tumor agent is an inhibitor of growth factor function. 24. The method of claim 23, wherein the inhibitor of growth factor function is trastuzumab. 25. The method of claim 18, wherein the anti-tumor agent is an antiangiogenic agent. 26. The method of claim 25, wherein the antiangiogenic agent is bevacizumab. 27. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00362## 28. The pharmaceutical composition of claim 1, wherein the compound has the Formula: ##STR00363##

Details for Patent 9,693,989

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2025-11-15
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2025-11-15
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2025-11-15
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2025-11-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.